Despite treatment with radical cystectomy, patients with muscle invasive bladder cancer (MIBC) have a poor survival. It has been reported that survival is worse in NMIBC patients who progressed to MIBC in comparison to patients with de novo MIBC.
Clear cell papillary renal cell carcinoma (CCPRCC) accounts for 2-4% of renal cortical tumors and was recently recognized by the World Health Organization in 2016 as a new tumor entity. Initially described in patients with end-stage renal disease (ESRD) by Tickoo et al,1 later studies found that CCPRCC also arises sporadically in patients with normal […]
Top-quality scientific content is what draws thousands of medical specialists to EAU’s Annual Congress, Europe’s largest urology meeting. Submit your original research by 1 February 2021, 23:59 CET, for the opportunity to present at the 36th Annual EAU Congress (EAU21) in Milan. To increase your chances of getting accepted, we have added four new subtopics: […]
In this manuscript, we highlight the importance of understanding the risk factors associated with a high probability for chemotherapy resistance in patients with advanced penile cancer. We highlight the limitations of second-line cytotoxic chemotherapy or radiation, with very poor patients’ survival. Therefore, it is very important for clinicians caring for penile cancer patients to investigate […]
To investigate the impact on intravesical recurrence and prognosis according to the ureteral ligation timing during radical nephroureterectomy for upper urinary tract urothelial carcinoma. We carried out a retrospective chart review of 664 patients with non-metastatic upper urinary tract urothelial carcinoma who underwent radical nephroureterectomy with ureteral ligation (supplementary analysis of JCOG1110A).
The purpose of our study was to establish a reliable and practical nomogram based on significant clinical factors to predict the overall survival (OS) and cancer-specific survival (CSS) of patients with germ cell testicular cancer (GCTC).
Clear cell renal cell carcinoma (ccRCC) is a common urological disease. Expression of the protein tyrosine phosphatase 12 gene (PTPN12) is decreased in many cancers; however, the relationship between PTPN12 gene function and renal cancer remains unclear.
Metastatic clear cell renal cell carcinoma (mccRCC) benefits from several treatment options in the first-line setting with VEGFR inhibitors and/or immunotherapy including anti-PD-L1 or anti-PD1 agents.
Published transcriptomic data from surgically removed metastatic clear cell renal cell carcinoma samples were analyzed from the genomic fabric paradigm (GFP) perspective to identify the best targets for gene therapy.
Our purpose was to study the effect of 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) positron emission tomography (PET)-computed tomography (CT) on staging/treatment recommendations of previously untreated prostate cancer.
